Going Beyond Distribution: How Commercialization Platforms Are Reshaping Pharma in Asia

Asia’s pharmaceutical markets are large, fast-growing and increasingly strategic for global pharma and biotech. At the same time, they remain deeply fragmented, spanning mature, publicly funded systems alongside emerging markets that are still heavily out of pocket. This diversity creates opportunity but also makes scaling across the region complex and resource intensive.

Download the full white paper: “Going Beyond Distribution: Commercialization Platforms Reshaping How Pharma Scales in Asia.”

A high-growth region defined by complexity

Asia-Pacific today represents a significant share of the global pharmaceutical market and continues to outpace Western markets in growth. However, it is not a homogenous market. Each country differs in its healthcare funding model, regulatory environment and go-to-market dynamics. In many emerging markets, private healthcare channels dominate and physician-led prescribing remains central to access.
Importantly, off-patent brands and branded generics continue to account for a large share of the pharma market, with longer product life cycles than in the U.S. or Europe. Commercial success in these markets is therefore driven as much by execution and local presence as by innovation.

A structural challenge for pharma and biotech

This fragmentation creates structural challenges for both global pharma companies and small and midsize biotechs. Building local affiliates across multiple markets is costly and operationally complex, particularly for companies with limited portfolios. At the same time, many multinational pharma companies are shifting focus toward innovation and priority markets, leaving mature brands in Asia under-resourced despite continued growth potential.
There is often a disconnect between the value embedded in these markets and the ability of companies to fully capture it.

The emergence of commercialization platforms

Asia’s pharma commercialization platforms are expanding to address this gap.
These platforms go beyond traditional distribution. They operate as full-service commercialization engines, combining regulatory, medical, market access, sales and distribution capabilities across multiple markets. By centralizing these functions, they enable faster launches, lower cost of entry and more efficient scaling across geographies.
In effect, they provide commercial infrastructure across multiple markets that companies can leverage without having to build local capabilities from scratch.

Scaling through partnerships, licensing and carve-outs

Commercialization platforms are already demonstrating their ability to scale products and portfolios across Asia. They are partnering with biotech companies to bring innovative therapies to market and in-licensing assets for regional expansion and acquiring mature brands through carve-outs to drive life cycle value.
This model allows platforms to aggregate portfolios, build operating leverage and create repeatable growth across markets, turning fragmented demand into scalable opportunity.

An increasingly attractive investment opportunity

Financial investors are increasingly recognizing the attractiveness of this model. Commercialization platforms offer a combination of scalable infrastructure, multiple growth levers and durable, cash-generative revenue streams.
The investment thesis is clear: build or acquire a multi-market commercial footprint, expand through business development and portfolio additions, and create value through scale and execution. Recent transactions across Asia underscore growing momentum and capital inflow into this space.

Redefining how pharma scales in Asia

In Asia’s diverse and complex markets, commercial reach and execution are emerging as critical sources of competitive advantage. Commercialization platforms enable pharmaceutical and biotech companies to unlock this value more effectively while creating a class of scalable, investable assets.
This shift is redefining how companies approach growth in the region, moving from market-by-market expansion to platform-led scaling.

For further insights into our analysis, download the full PDF.